Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
International Journal of Neuropsychopharmacology · 2023
DOI: 10.1093/ijnp/pyad035 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2023. Verfasst von Ravi Anand und 4 weiteren Autor:innen. Beteiligte Einrichtung: APC, St. Moritz, Switzerland. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Newron Pharmaceuticals SpA, Contract Research Organization.
Abstract (Originalsprache)
Results from a pilot, 6-week, randomized, open-label, rater-blinded study, with 46-week extension, indicate very good tolerability with exceptional, clinically important, increasing efficacy of evenamide (7.5, 15, and 30 mg bid), a glutamate modulator, as add-on treatment to antipsychotics in 161 treatment-resistant, schizophrenia patients. Ninety-five percent of patients completed 6 weeks (1 discontinued for adverse event), and 89% continued in the extension. Results from the first 100 patients enrolled showed very low attrition over 1 year (77 completers); data pooled from all dose groups showed the Positive and Negative Syndrome Scale total score improved significantly (P < .001; paired t test; last observation carried forward [LOCF]) from baseline at 6 weeks (−9.4), 6 months (−12.7), and 1 year (−14.7); similarly, the proportion of responders (≥20% improvement) increased over time from 6 weeks (16.5%) to 6 months (39%) to 1 year (47.4%). Noteworthy improvement was also observed at each timepoint on the Clinical Global Impression - Severity scale and Clinical Global Impression of Change, indicating progressively increasing efficacy of evenamide up to 1 year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- APC, St. Moritz, Switzerland.
- Newron Pharmaceuticals SpA, Bresso, Italy.
- CliniRx Research Pvt Ltd, New Delhi, India.
- NeurWrite LLC, Morristown, NJ, USA.
ORCID-Profile: Giovanni Chinellato
Förderung
- Newron Pharmaceuticals SpA
- Contract Research Organization
Zitieren
APA
Anand, R., Turolla, A., Chinellato, G., Roy, A., & Hartman, R. D. (2023). Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyad035
Vancouver
Anand R, Turolla A, Chinellato G, Roy A, Hartman RD. Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia. International Journal of Neuropsychopharmacology. 2023. doi:10.1093/ijnp/pyad035
BibTeX
@article{Anand2023,
author = {Anand, Ravi and Turolla, Alessio and Chinellato, Giovanni and Roy, Arjun and Hartman, Richard D},
title = {Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia},
journal = {International Journal of Neuropsychopharmacology},
year = {2023},
doi = {10.1093/ijnp/pyad035}
}
EUVIMED